A Human Absorption, Distribution, Metabolism and Excretion (hADME) and Absolute Bioavailability Trial After a Single Micro-tracer Dose of BI 1584862 (C-14) and a Single, Concomitant, Intravenous Micro-dose of BI 1584862 (C-13) in Healthy Male Trial Participants (a Phase I, Open-label, Non-randomised, Single-dose, Fixed-sequence Trial)
Latest Information Update: 10 Mar 2026
At a glance
- Drugs BI 1584862 (Primary)
- Indications Dry age-related macular degeneration
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 04 Mar 2026 Status changed from recruiting to active, no longer recruiting.
- 04 Feb 2026 Status changed from not yet recruiting to recruiting.
- 27 Dec 2025 New trial record